Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Premenopausal Breast Cancer × exemestane × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 199 Neoplasm Metastasis 17 Neoplasms 6 Breast Neoplasms, Male 6 Breast Diseases 5 Carcinoma, Intraductal, Noninfiltrating 4 Obesity 3 Breast Carcinoma In Situ 3 Breast Cancer Metastatic 3 Recurrence 2 Neoplasms by Site 2 Bulbo-Spinal Atrophy, X-Linked 2 Arthralgia 2 Advanced Breast Cancer 2 Vitamin D Deficiency 1 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Thoracic Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sleep Wake Disorders 1 Skin Diseases 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Primary Breast Cancer ER+ve 1 Premenopausal Breast Cancer 1 Post Menopausal Women With Early Breast Cancer 1 Patient Acceptance of Health Care 1 Pain 1 Ovarian Neoplasms 1 Nutrition Disorders 1

Interventions

Leuprolide 2 pembrolizumab 1 exemestane 1 Tamoxifen 1 Surgical Procedures, Operative 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02990845 2023-02-22

PEER

National Taiwan University Hospital

Phase 1/2 Terminated

Premenopausal Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡